Working… Menu

Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women (ASAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01131624
Recruitment Status : Completed
First Posted : May 27, 2010
Last Update Posted : May 29, 2015
Pierrel Research Europe GmbH
Information provided by (Responsible Party):
Vifor Inc.

Brief Summary:
The purpose of this study is to look at how well Ferric Carboxymaltose, an intravenous iron therapy (iron that is infused directly into your body through a vein), compares with ferrous sulphate capsules taken by mouth in the treatment of iron deficiency anaemia during pregnancy.

Condition or disease Intervention/treatment Phase
Anaemia Drug: ferrous sulphate Drug: Ferinject Phase 3

Detailed Description:

This is an open-label, multicentre, randomised, 2-arm study to assess the efficacy and safety of FCM compared to oral iron in pregnant women with IDA.

During the screening period (Days -10 to 0 before randomisation), subjects will be selected based on eligibility criteria. Subjects who meet all of the inclusion criteria and none of the exclusion criteria will undergo baseline assessments at baseline (Day 0) prior to the first dose of study medication.

Subjects will be randomised to receive either intravenous (IV) iron (FCM, 1,000-1,500 mg) or oral iron (ferrous sulphate, 100 mg iron twice a day; total dose 200 mg/day).

The treatment period will begin with the infusion of FCM or the intake of oral iron on Day 0.

All subjects will return for assessment of efficacy and safety at Weeks 3, 6, 9, 12 and at delivery (or whichever comes first).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 252 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multicentre, Randomised, 2-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Pregnant Women
Study Start Date : May 2010
Actual Primary Completion Date : May 2014
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia Iron

Arm Intervention/treatment
Active Comparator: Ferric carboxymaltose

Subjects with bw ≥66 kg will receive an infusion of 1,000 mg iron as FCM and after 1 week a further 500 mg iron as FCM, depending on Hb at screening.

subjects with bw <66 kg, 2-3 infusions of 500 mg iron as FCM will be administered within 2 weeks from baseline, depending on Hb at screening

Drug: Ferinject
1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.
Other Names:
  • Ferric carboxymaltose
  • FCM

Active Comparator: Oral Iron
Oral Iron oral iron preparation will be provided at 200 mg iron per day in a convenient dosage schedule.
Drug: ferrous sulphate
200 mg iron per day in a convenient dosage schedule.
Other Name: Oral Iron

Primary Outcome Measures :
  1. Average Hb increase after 3 weeks in FCM compared to oral iron treated subjects (superiority). [ Time Frame: 3 weeks after baseline ]

Secondary Outcome Measures :
  1. Change in Hb from baseline at Week 6 [ Time Frame: 6 weeks after baseline ]
  2. Change in Hb from baseline at Week 9 [ Time Frame: 9 weeks after baseline ]
  3. Change in Hb from baseline at Week 12 [ Time Frame: 12 weeks after baseline ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pregnant women aged ≥18, gestational week ≥20, ≤33 at baseline visit with normal antenatal screening test results.
  • Iron deficiency anaemia defined as Hb concentration ≥8 g/dl and ≤10.4 g/dL and serum ferritin ≤20 mcg/L at screening.
  • Demonstrated the ability to understand the requirements of the study, abide by the study restrictions, and agree to return for the required assessments. Patients (or their representative) must provide written informed consent for their participation in the study.

Exclusion Criteria:

  • Blood transfusion, erythropoietin treatment, parenteral iron or oral iron treatment (1 month prior to screening) or anticipated need for a blood transfusion during the study.
  • Anaemia not caused by iron deficiency (e.g., aplastic, megaloblastic or haemolytic anaemia) or related to acute or ongoing, haemoglobinopathies, rheumatic and other chronic diseases, autoimmune diseases, malignancies, bone marrow diseases, enzyme defects and drug induced anaemia.
  • Acute or chronic infection, clinically relevant active inflammatory disease (C-reactive protein >10 mg/dl or outside reference range), any acute infection at screening.
  • Pre-eclampsia.
  • Multiple pregnancy.
  • Evidence on any significant abnormalities on anomaly ultrasound.
  • Haemochromatosis or other iron storage disorders.
  • Folate deficiency (S-folate <4.5 nmol/L) at screening.
  • Vitamin B12 deficiency (S-cobalamin <145 pmol/L) at screening.
  • Serious medical condition, uncontrolled systemic disease or any other medical condition that, in the judgment of the Investigator, prohibits the patient from entering or potentially completing the study.
  • Known chronic renal failure (defined as creatinine clearance <30 mL/min calculated by Cockcroft-Gault or modification of diet in renal disease formula).
  • Severe cardiovascular diseases.
  • Known human immunodeficiency virus/acquired immunodeficiency syndrome, hepatitis B virus or hepatitis C virus infection.
  • Inability to fully comprehend and/or perform study procedures in the Investigator's opinion
  • History of endocrine disorders
  • Ongoing significant neurological or psychiatric disorders including psychotic disorders or dementia
  • Recent significant bleeding/surgery (within the 3 months prior to screening).
  • Chronic/acute hepatic disorder or elevating of liver enzymes (aspartate aminotransferase, alanine aminotransferase) over 2 times above the upper normal limit at screening.
  • Participation in any other interventional study since estimated conception and throughout study participation.
  • Known hypersensitivity to FCM or other IV iron preparations.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01131624

Layout table for location information
Australia, Victoria
The Northern Hospital
Epping, Victoria, Australia, 3076
Vivantes Klinikum Neukölln, Klinikum für Geburtsmedizin
Berlin, Germany, 12351
Klinik Für Frauenheilkunde und Geburtshilfe Universitätsklinikum Marburg
Marburg, Germany, 35043
Perinatalzentrum, Klinikum Innenstadt LMU
München, Germany, 80337
Kvinnokliniken, Falu lasarett
Falun, Sweden, SE-791
Kvinnokliniken, University Hospital
Lund, Sweden, SE-221
Kvinnokliniken, Karolinska University Hospital
Stockholm, Sweden, 17176
Karolinska Universitetssjukhuset Huddinge, Centrum för fostermedicin KK
Stockholm, Sweden, SE-141
University Hospital, Dept of obstetrics and gynecology Uppsala
Uppsala, Sweden, SE-751
Universitätsspital Basel, Geburtshilfe und Schwangerschaftsmedizin Frauenklinik
Basel, Switzerland, 4031
Inselspital, Department of Obstetrics and Gynecology
Bern, Switzerland, 3010
Bern, Switzerland, 3013
HUG, Département de Gynécologie-Obstétrique
Genève, Switzerland, 1211
CHUV, Département de Gynécologie-Obstétrique
Lausanne, Switzerland, 1011
OR Lugano, sede Ospedale Civico, Clinica ginecologia ostetricia
Lugano, Switzerland, 6900
Universitätsspital Zürich, Departement Frauenheilkunde
Zürich, Switzerland, 8091
Cukurova University Hospital
Adana, Turkey, 01330
Istanbul Uni. Ist. Med. Faculty
Istanbul, Turkey, 34093
Zeynep Kamil Hospital, Arakiyeci Haci Mehmet Mahallesi.
Istanbul, Turkey, 34668
Dr. Kutfi Kirdar Kartal Research and Education Hospital
Istanbul, Turkey, 34890
Sponsors and Collaborators
Vifor Inc.
Pierrel Research Europe GmbH
Layout table for investigator information
Principal Investigator: Christian Breymann University of Zurich

Layout table for additonal information
Responsible Party: Vifor Inc. Identifier: NCT01131624     History of Changes
Other Study ID Numbers: FER-ASAP-2009-01
First Posted: May 27, 2010    Key Record Dates
Last Update Posted: May 29, 2015
Last Verified: December 2014
Keywords provided by Vifor Inc.:
Iron deficiency
Additional relevant MeSH terms:
Layout table for MeSH terms
Ferric Compounds
Anemia, Iron-Deficiency
Hematologic Diseases
Anemia, Hypochromic
Iron Metabolism Disorders
Metabolic Diseases
Trace Elements
Growth Substances
Physiological Effects of Drugs